# Firibastat in Treatment-resistant Hypertension

Study · id `cardio:ct-nct04277884` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04277884](<https://clinicaltrials.gov/study/NCT04277884>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04277884

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.

## Technical summary

Registry record NCT04277884. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-25 (actual); primary completion 2022-08-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 515 participants (enrolled count; ClinicalTrials.gov record NCT04277884, source copy `cardio:ctgov-nct04277884-2022-10-20`, retrieved 2026-11-18)
- Started: 2020-06-25 (actual) (ClinicalTrials.gov record NCT04277884, source copy `cardio:ctgov-nct04277884-2022-10-20`, retrieved 2026-11-18)
- Primary completion: 2022-08-30 (actual) (ClinicalTrials.gov record NCT04277884, source copy `cardio:ctgov-nct04277884-2022-10-20`, retrieved 2026-11-18)
- Completion: 2022-09-20 (actual) (ClinicalTrials.gov record NCT04277884, source copy `cardio:ctgov-nct04277884-2022-10-20`, retrieved 2026-11-18)
- Countries: United States; Czechia; France; Germany; Poland; Spain (ClinicalTrials.gov record NCT04277884, source copy `cardio:ctgov-nct04277884-2022-10-20`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04277884-2022-10-20`, retrieved 2026-11-18)

## The registry's words

- Brief title: Firibastat in Treatment-resistant Hypertension
- Acronym: FRESH
- Condition: Hypertension
- Intervention (Drug): Firibastat
- Intervention (Drug): Placebo
- Lead sponsor: Quantum Genomics SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Quantum Genomics SA (`cardio:org-quantum-genomics-sa`)

## Provenance

Content hash: 9395ba26788b186373dcc90f40b714910c985795ca5bad0625dbe7abed0daa7d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
